Reporting on 16 years of laboratory capacity building while exploring the future of WOAH's Laboratory Twinning Programme.

Animal health laboratories are an increasingly important part of safeguarding animal and public health due to their role in surveillance and diagnostics of animal diseases, food safety, and in the development and production of medicinal products, vaccines, and diagnostic tools. Despite their importance, the global distribution of veterinary laboratory expertise is uneven, with greater concentration of reference laboratories in wealthier countries. To address this issue, the World Organization for Animal Health (WOAH, founded as OIE) created a Laboratory Twinning Programme in 2006. The paper will briefly review this Programme in the context of an increasingly populated global health security field, based on a literature review and on a combination of public and internal WOAH data and describe the implementation of the Programme in the past 16 years, noting the drivers for project implementation, its links with the global livestock biomass distribution and with the current distribution of veterinary laboratory expertise. There has been broad uptake and diversity in the focus of the twinning projects implemented in WOAH Member Countries. The Laboratory Twinning Programme would benefit from an evaluation that looks at its outcomes and quantifiable impact in beneficiary countries. A case is made for the development of a monitoring and evaluation system tailored to the Programme's specificities.

From OIE standards to responsible and prudent use of antimicrobials: supporting stewardship for the use of antimicrobial agents in animals.

The global action plan (GAP) on antimicrobial resistance (AMR) advocated the development of national action plans on AMR and the implementation of plans aimed at preventing, combating and monitoring AMR. The World Organisation for Animal Health (OIE)'s strategy on AMR and the prudent use of antimicrobials is aligned with the GAP and recognizes the importance of a One Health approach. This paper reviews the goals, tools and strategies that the OIE has in place to support its Members, envisioning an increased awareness of them and ultimately an increased implementation of the OIE standards. The OIE standards are endorsed by vote of all the 182 Members and are recognized by the World Trade Organization (WTO). The OIE List of Antimicrobial Agents of Veterinary Importance, which includes specific recommendations on the use of antimicrobial agents, is also of particular importance for antimicrobial stewardship. OIE's antimicrobial use (AMU) data collection started in 2015 and has been developed in particular to measure trends in AMU. An annual report is published as an output of this data collection. An AMU IT database system is being developed. The OIE provides assistance to its 182 Members to strengthen the implementation of OIE standards via its support of good governance, the Performance of Veterinary Services (PVS) Pathway, PVS Veterinary Legislation Support Program and training of veterinarians and veterinary paraprofessionals. In parallel, the OIE Observatory is a recent initiative, specifically targeting the monitoring of the implementation of the OIE standards. Cooperation agreements between the OIE and intergovernmental organizations and non-governmental organizations are instrumental for the increase of the dissemination and implementation of the OIE standards and guidelines.

OIE Annual Report on Antimicrobial Agents Intended for Use in Animals: Methods Used.

For over two decades, the World Organisation for Animal Health (OIE) has engaged in combatting antimicrobial resistance (AMR) through a One Health approach. Monitoring of antimicrobial use (AMU) is an important source of information that together with surveillance of AMR can be used for the assessment and management of risks related to AMR. In the framework of the Global Action Plan on AMR, the OIE has built a global database on antimicrobial agents intended for use in animals, supported by the Tripartite (World Health Organization (WHO), Food and Agriculture Organization of the United Nations (FAO) and OIE) collaboration. The OIE launched its first annual data collection in 2015 and published the Report in 2016. The second Report, published in 2017, introduced a new methodology to report quantitative data in the context of relevant animal populations, and included for the first time an annual analysis of antimicrobial quantities adjusted for animal biomass on a global and regional level. A continuing annual increase of countries participating in the data collection demonstrates the countries engagement for the global development of monitoring and surveillance systems in line with OIE international standards. Where countries are not yet able to contribute their quantitative data, their reports also highlight the barriers that impede them in data collection, analysis and/or reporting. The OIE Reports show annual global and regional estimates of antimicrobial agents intended for use in animals adjusted for animal biomass, as represented by the quantitative data reported by countries to the OIE. The OIE advises caution in interpretation of estimates made in the first few years of reporting recognizing some important limitations faced by countries as they develop their monitoring systems. The OIE remains strongly committed to supporting its Members in developing robust and transparent measurement and reporting mechanisms for AMU.

Pharmacokinetics of low-dose methotrexate in healthy beagle dogs.

Methotrexate may be an alternative to ciclosporin in the treatment of canine atopic dermatitis (cAD) as suggested by recent data. The aim of the study was to investigate both the tolerance and the pharmacokinetic behavior of methotrexate (MTX) in plasma, following intravenous (i.v.), subcutaneous (s.c.) or oral (OR) administration over several weeks. Six healthy dogs were given oral MTX once a week, respectively, per dog at 2.5 mg/1 week, 5 mg/4 weeks, 7.5 mg/3 weeks, 10 mg/6 weeks and 12.5 mg/5 weeks. No clinically relevant abnormalities of laboratory parameters were noticed. A high inter-individual variation of MTX plasma concentration was observed with a suspicion of saturation phenomenon in absorption. To compare with other routes of administration, six healthy beagle dogs followed a crossover design study at 7.5 mg per dog MTX. The absolute bioavailability was 93% for SC injection and 30% for the oral route. The inter-individual variability was quite low following SC administration compared to oral route. Just as in human, given the substantial variability of oral absorption, clinicians cannot assume consistent oral bioavailability of MTX. Therefore, they may consider switching dogs to the SC route in case of absence of clinical response with a weekly oral dose.